To summarize the current status, mechanisms, challenges, and future directions of immunotherapy in advanced rectal cancer.
Data Sources
Published clinical trials, translational studies, and mechanistic reports on immunotherapeutic strategies for colorectal and rectal cancer.
Data Summary
Immune checkpoint inhibitors (ICIs), particularly PD-1/PD-L1 and CTLA-4 blockade, show promise in MSI-H rectal cancer, while combination therapies are under investigation for microsatellite stable (MSS) tumors. Tumor vaccines and T-cell-based approaches, such as CAR-T and TCR-engineered therapies, are emerging strategies. Major barriers include immune evasion, microenvironment heterogeneity, and resistance mechanisms in MSS disease.
Conclusions
Immunotherapy is transforming the treatment landscape of advanced rectal cancer, yet challenges persist. Continued mechanistic exploration and rational combination strategies are essential to improve response rates and expand benefit to MSS patients.
BaidounFElshiwyKElkeraieY, et al.Colorectal cancer epidemiology: recent trends and impact on outcomes. Curr Drug Targets2021; 22: 998–1009.
2.
SarafARobertsHJWoJY, et al.Optimal neoadjuvant strategies for locally advanced rectal cancer by risk assessment and tumor location. J Natl Compr Canc Netw2022; 20: 1177–1184.
3.
GaneshKStadlerZKCercekA, et al.Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol2019; 16: 361–375.
4.
BillerLHSchragD. Diagnosis and treatment of metastatic colorectal cancer: a review. JAMA2021; 325: 669–685.
5.
BachetJBBenoistSMasL, et al.Neoadjuvant treatment for rectal cancer. Bull Cancer2021; 108: 855–867.
6.
ThanikachalamKKhanG. Colorectal cancer and nutrition. Nutrients2019; 11: 20190114.
7.
CohenRRousseauBVidalJ, et al.Immune checkpoint inhibition in colorectal cancer: microsatellite instability and beyond. Target Oncol2020; 15: 11–24.
8.
JiangYChenMNieH, et al.PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother2019; 15: 1111–1122.
DermaniFKSamadiPRahmaniG, et al.PD-1/PD-L1 immune checkpoint: potential target for cancer therapy. J Cell Physiol2019; 234: 1313–1325.
11.
KongJCSoucisseMMichaelM, et al.Total neoadjuvant therapy in locally advanced rectal cancer: a systematic review and metaanalysis of oncological and operative outcomes. Ann Surg Oncol2021; 28: 7476–7486.
12.
XiaLLiuYWangY. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current Status and future directions. Oncologist2019; 24: S31–S41.
13.
WuQJiangLLiSC, et al.Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway. Acta Pharmacol Sin2021; 42: –9.
14.
HuangMYJiangXMWangBL, et al.Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. Pharmacol Ther2021; 219: 107694.
15.
ChenKWangXYangL, et al.The anti-PD-1/PD-L1 immunotherapy for gastric esophageal cancer: a systematic review and meta-analysis and literature review. Cancer Control2021; 28: 1073274821997430.
16.
MasugiYNishiharaRYangJ, et al.Tumour CD274 (PD-L1) expression and T cells in colorectal cancer. Gut2017; 66: 1463–1473.
17.
YiMZhengXNiuM, et al.Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer2022; 21: 28.
18.
GuidaAMSensiBFormicaV, et al.Total neoadjuvant therapy for the treatment of locally advanced rectal cancer: a systematic minireview. Biol Direct2022; 17: 16.
19.
RotmanJden OtterLASBleekerMCG, et al.PD-L1 and PD-L2 expression in cervical cancer: regulation and biomarker potential. Front Immunol2020; 11: 596825.
20.
ZhangSYuMChenD, et al.Role of MRI-based radiomics in locally advanced rectal cancer (review). Oncol Rep2022; 47: 20211222.
21.
TrojanJStintzingSHaaseO, et al.Complete pathological response after neoadjuvant short-course immunotherapy with ipilimumab and nivolumab in locally advanced MSI-H/dMMR rectal cancer. Oncologist2021; 26: e2110–e2114.
22.
LeDTKimTWVan CutsemE, et al.Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol2020; 38: 11–19.
23.
AndreTShiuKKKimTW, et al.Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med2020; 383: 2207–2218.
24.
ChenMJiangMWangX, et al.Envafolimab - first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors. Expert Opin Biol Ther2022; 22: 1227–1232.
MendisSToYHTieJ. Biomarkers in locally advanced rectal cancer: a review. Clin Colorectal Cancer2022; 21: 36–44.
27.
OvermanMJLonardiSWongKYM, et al.Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol2018; 36: 773–779.
28.
Salas-BenitoDPerez-GraciaJLPonz-SarviseM, et al.Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov2021; 11: 1353–1367.
29.
ReeAHHamreHKerstenC, et al.Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): initial results from the randomized METIMMOX study. J Clin Oncol2021; 39: 3556–3556.
30.
FumetJDIsambertNHervieuA, et al.Phase ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open2018; 3: e000375.
31.
PietrantonioFMoranoFLonardiS, et al.383O MAYA trial: temozolomide (TMZ) priming followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite stable (MSS), MGMT silenced metastatic colorectal cancer (mCRC). Ann Oncol2021; 32: S530–S531.
32.
BodyAPrenenHLamM, et al.Neoadjuvant therapy for locally advanced rectal cancer: recent advances and ongoing challenges. Clin Colorectal Cancer2021; 20: 29–41.
33.
LiaoCKKuoYTLinYC, et al.Neoadjuvant short-course radiotherapy followed by consolidation chemotherapy before surgery for treating locally advanced rectal cancer: a systematic review and meta-analysis. Curr Oncol2022; 29: 3708–3727.
34.
ParikhARSzabolcsAAllenJN, et al.Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Nat Cancer2021; 2: 1124–1135.
35.
HodiFSLawrenceDLezcanoC, et al.Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res2014; 2: 632–642.
36.
GrotheyATaberneroJArnoldD, et al.Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): findings from cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy. Ann Oncol2018; 29: viii714–viii715.
37.
Jimenez-RodriguezRGarcia-AguilarJ. Non surgical treatment in patients with advanced rectal cancer. Cir Esp (Engl Ed)2021; 99: 401–403.
38.
BandoHTsukadaYItoM, et al.Novel Immunological Approaches in the Treatment of Locally Advanced Rectal Cancer. Clin Colorectal Cancer2022; 21: –9.
39.
HellmannMDKimTWLeeCB, et al.Phase ib study of atezolizumab combined with cobimetinib in patients with solid tumors. Ann Oncol2019; 30: 1134–1142.
40.
ChalabiMFanchiLFDijkstraKK, et al.Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med2020; 26: 566–576.
41.
ChenEXJonkerDJLoreeJM, et al.Effect of combined immune checkpoint inhibition vs best supportive care alone in patients with advanced colorectal cancer: the Canadian cancer trials group CO.26 study. JAMA Oncol2020; 6: 831–838.
42.
OminelliJValadaoMAraujoROC, et al.The evolving field of neoadjuvant therapy in locally-advanced rectal cancer: evidence and prospects. Clin Colorectal Cancer2021; 20: 288–298.
43.
Glynne-JonesRHarrisonM. Should the RAPIDO schedule represent standard of care in locally advanced rectal cancer?Ann Oncol2022; 33: 745–746.
44.
O'RourkeMGJohnsonMLanaganC, et al.Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother2003; 52: 387–395.
45.
CaoJXZhangXYLiuJL, et al.Validity of combination active specific immunotherapy for colorectal cancer: a meta-analysis of 2993 patients. Cytotherapy2015; 17: 1746–1762.
46.
ZinsMSantiagoI. MRI For T restaging of locally advanced rectal cancer following neoadjuvant chemotherapy and radiation therapy. Radiology2022; 305: 373–374.
47.
ChanJDLaiJSlaneyCY, et al.Cellular networks controlling T cell persistence in adoptive cell therapy. Nat Rev Immunol2021; 21: 769–784.
48.
TranERobbinsPFLuYC, et al.T-Cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med2016; 375: 2255–2262.
49.
SternerRCSternerRM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J2021; 11: 69.
50.
FeinsSKongWWilliamsEF, et al.An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer. Am J Hematol2019; 94: S3–S9.
51.
LinHChengJMuW, et al.Advances in universal CAR-T cell therapy. Front Immunol2021; 12: 744823.
52.
SermerDBrentjensR. CAR T-cell therapy: full speed ahead. Hematol Oncol2019; 37: 95–100.
53.
ChenGMChenCDasRK, et al.Integrative bulk and single-cell profiling of premanufacture T-cell populations reveals factors mediating long-term persistence of CAR T-cell therapy. Cancer Discov2021; 11: 2186–2199.
54.
ZhangCWangZYangZ, et al.Phase I escalating-dose trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther2017; 25: 1248–1258.
55.
FahyMRKellyMEPower FoleyM, et al.The role of intraoperative radiotherapy in advanced rectal cancer: a meta-analysis. Colorectal Dis2021; 23: 1998–2006.
56.
KoukourakisMIKavazisCGiagtzidisA, et al.Postoperative hypofractionated-accelerated radiotherapy (HypoAR) for locally advanced rectal cancer. Jpn J Clin Oncol2022; 52: 493–498.
57.
Glynne-JonesRGlynne-JonesS. The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer. Lancet Oncol2021; 22: e314–e326.
58.
PhamTTLimSLinM. Predicting neoadjuvant chemoradiotherapy response with functional imaging and liquid biomarkers in locally advanced rectal cancer. Expert Rev Anticancer Ther2022; 22: 1081–1098.
59.
ArefAAbdallaA. Total neoadjuvant therapy for locally advanced rectal cancer: induction or consolidation chemotherapy?J Clin Oncol2022; 40: 2515–2519.
60.
GeorgescuMTPatrascuTSerbanescuLG, et al.When should we expect curative results of neoadjuvant treatment in locally advanced rectal cancer patients?Chirurgia (Bucur)2021; 116: 16–23.
